ASH 2017

Area: Hematology

Location: Atlanta, United States

Date: December 9 to December 12

Description:

American Society of Hematology.


Search in Scientific Content:
Date
Filters:
A Randomiz
10:23

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Presenter: Gary E. Raskob
Hematology
Phase 3 Ra
6:36

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Presenter: Jesús F. San Miguel
Hematology
Venetoclax
10:35

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

Presenter: John F. Seymour
Hematology
Results of
9:01

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Presenter: Robert K. Zeldin
Hematology
Anti-CCR4 ...
6:57

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

Presenter: Youn H. Kim
Hematology
Initial Re
7:52

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Presenter: Peter Hillmen
Hematology
Brentuxima
7:07

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Presenter: Joseph M. Connors
Hematology
Long-Term
6:51

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Presenter: Sattva S. Neelapu
Hematology
Durable Cl
11:13

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Presenter: James N. Kochenderfer
Hematology
Chronic my
7:05

Chronic myeloid leukemia: First-line drug of choice

Presenter: Elias Jabbour
Hematology
Dissecting
4:31

Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL

Presenter: Eric Eldering
Hematology
Initial Re
2:51

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Presenter: Peter Hillmen
Hematology
Initial Re
1:24

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Presenter: Stephen J. Schuster
Hematology
Sequential
7:20

Sequential Brentuximab Vedotin before and after Adriamycin, Vinblastine, and Dacarbazine for Older Patients with Untreated Classical Hodgkin Lymphoma: Final Results from a Multicenter Phase II Study

Presenter: Andrew M. Evens
Hematology
Murano Stu
7:48

Murano Study

Presenter: John F. Seymour
Hematology
GADOLIN St
6:02

GADOLIN Study News

Presenter: Bruce D. Cheson
Hematology

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASH 2016

2016-12-03 - 2016-12-06
San Diego, United States

ASH 2015

2015-12-05 - 2015-12-08
Orlando, United States

EHA 2015

2015-06-11 - 2015-06-14
Vienna, Australia